Literature DB >> 30830341

Omega-6-derived oxylipin changes in serum of patients with hepatitis B virus-related liver diseases.

Yonghai Lu1,2, Jinling Fang3, Li Zou3, Liang Cui4, Xu Liang5, Seng Gee Lim6, Yock-Young Dan7, Choon Nam Ong3,5.   

Abstract

INTRODUCTION: Chronic hepatitis B virus (HBV) infection is the main etiologic risk factor for hepatocellular carcinoma (HCC). Early studies indicated that the increase of omega-6-derived oxylipins may be involved in the pathogenesis of HBV-related HCC, yet their changes during the distinct clinical phases of chronic HBV infection remain unclear. To fill this gap, in this study we investigated the omega-6-derived oxylipin profiles in patients with three major clinical stages of chronic HBV infection (chronic hepatitis B, liver cirrhosis, and HCC).
METHODS: Eighteen omega-6-derived oxylipins were quantified in serum samples of 34 patients with chronic hepatitis B, 46 patients with HBV-related liver cirrhosis, 38 patients with HBV-related HCC, and 50 healthy controls using liquid chromatography tandem mass spectrometry.
RESULTS: Seven oxylipins were found to be altered in patients with HBV-related liver diseases, including 9,10-dihydroxyoctadecenoic acid (9,10-DiHOME), 12,13-DiHOME, 14,15-dihydroxyeicosatrienoic acid (14,15-DiHETrE), 13-hydroxyoctadecadienoic acid (13-HODE), 12-hydroxyeicosatetraenoic acid (12-HETE), 11-HETE, and thromboxane B2 (TXB2). Of these, three oxylipins derived from the cytochrome P450 (CYP450) pathways including 9,10-DiHOME, 12,13-DiHOME, and 14,15-DiHETrE were found to be associated with the levels of α-fetoprotein (AFP), a tumor marker. In combination with AFP, age, and gender, a combination of these seven differential oxylipins could significantly enhance the prediction of HBV-related liver diseases, particularly for liver cirrhosis (p < 0.05).
CONCLUSION: This study for the first time shows the correlations between CYP450-derived oxylipins and the progression of chronic HBV infection, and sheds a new light on the surveillance of HBV-related live diseases using oxylipins.

Entities:  

Keywords:  HBV; HCC; LC–MS/MS; Liver cirrhosis; Omega-6-derived oxylipins

Mesh:

Substances:

Year:  2018        PMID: 30830341     DOI: 10.1007/s11306-018-1326-z

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  20 in total

1.  Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.

Authors:  S H Bae; E S Jung; Y M Park; B S Kim; B K Kim; D G Kim; W S Ryu
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2.

Authors:  Yi Yu; Rui Gong; Yongxin Mu; Yanni Chen; Chengliang Zhu; Zhichen Sun; Mingzhou Chen; Yingle Liu; Ying Zhu; Jianguo Wu
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

Review 3.  Role of diets rich in omega-3 and omega-6 in the development of cancer.

Authors:  Sara Huerta-Yépez; Ana B Tirado-Rodriguez; Oliver Hankinson
Journal:  Bol Med Hosp Infant Mex       Date:  2016-11-30

4.  Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2.

Authors:  Changliang Shan; Fuqing Xu; Shuai Zhang; Jiacong You; Xiaona You; Liyan Qiu; Jie Zheng; Lihong Ye; Xiaodong Zhang
Journal:  Cell Res       Date:  2010-04-13       Impact factor: 25.617

5.  Association between E-cadherin expression by human colon, bladder and breast cancer cells and the 13-HODE:15-HETE ratio. A possible role of their metastatic potential.

Authors:  M E Pasqualini; V L Heyd; P Manzo; A R Eynard
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-01       Impact factor: 4.006

Review 6.  Cytochrome P450 and liver diseases.

Authors:  J-P Villeneuve; V Pichette
Journal:  Curr Drug Metab       Date:  2004-06       Impact factor: 3.731

7.  Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study.

Authors:  Woon-Puay Koh; Yock Young Dan; George Boon-Bee Goh; Aizhen Jin; Renwei Wang; Jian-Min Yuan
Journal:  Liver Int       Date:  2015-10-27       Impact factor: 5.828

8.  Plasma fatty acids, oxylipins, and risk of myocardial infarction: the Singapore Chinese Health Study.

Authors:  Ye Sun; Hiromi W L Koh; Hyungwon Choi; Woon-Puay Koh; Jian-Min Yuan; John W Newman; Jin Su; Jinling Fang; Choon Nam Ong; Rob M van Dam
Journal:  J Lipid Res       Date:  2016-05-24       Impact factor: 5.922

9.  Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.

Authors:  Asem I Fitian; David R Nelson; Chen Liu; Yiling Xu; Miguel Ararat; Roniel Cabrera
Journal:  Liver Int       Date:  2014-04-28       Impact factor: 5.828

10.  Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in cardiac surgery.

Authors:  Katrin Strassburg; Annemarie M L Huijbrechts; Kirsten A Kortekaas; Jan H Lindeman; Theresa L Pedersen; Adrie Dane; Ruud Berger; Arjan Brenkman; Thomas Hankemeier; John van Duynhoven; Eric Kalkhoven; John W Newman; Rob J Vreeken
Journal:  Anal Bioanal Chem       Date:  2012-07-20       Impact factor: 4.142

View more
  5 in total

Review 1.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

2.  Endoscopic ultrasound-guided sampling and profiling of portal circulation in human patients for metabolic research studies and biomarker assessment.

Authors:  Marvin Ryou; Nicholas Stylopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-09-02       Impact factor: 4.052

3.  Gigantol ameliorates CCl4-induced liver injury via preventing activation of JNK/cPLA2/12-LOX inflammatory pathway.

Authors:  Yaru Xue; Qiangqiang Deng; Qingli Zhang; Zhenghua Ma; Binfan Chen; Xiaolu Yu; Huige Peng; Sheng Yao; Jia Liu; Yang Ye; Guoyu Pan
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

4.  LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis.

Authors:  Hong Y Pan; Qing Q Wu; Qiao Q Yin; Yi N Dai; Yi C Huang; Wei Zheng; Tian C Hui; Mei J Chen; Ming S Wang; Jia J Zhang; Hai J Huang; Yong X Tong
Journal:  ACS Omega       Date:  2021-01-04

5.  A Novel Role for Cytochrome P450 Epoxygenase Metabolites in Septic Shock.

Authors:  Timothy N Jones; Leila Janani; Anthony C Gordon; Farah Al-Beidh; David B Antcliffe
Journal:  Crit Care Explor       Date:  2022-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.